H2AC8
gene geneOn this page
Also known as H2A/aH2A.1
Summary
H2AC8 (H2A clustered histone 8, HGNC:4724) is a protein-coding gene on chromosome 6p22.2, encoding Histone H2A type 1-B/E (P04908). Core component of nucleosome. It is a selective cancer dependency (DepMap: 29.3% of cell lines).
Histones are basic nuclear proteins that are responsible for the nucleosome structure of the chromosomal fiber in eukaryotes. Nucleosomes consist of approximately 146 bp of DNA wrapped around a histone octamer composed of pairs of each of the four core histones (H2A, H2B, H3, and H4). The chromatin fiber is further compacted through the interaction of a linker histone, H1, with the DNA between the nucleosomes to form higher order chromatin structures. This gene is intronless and encodes a replication-dependent histone that is a member of the histone H2A family. Transcripts from this gene lack polyA tails; instead, they contain a palindromic termination element. This gene is found in the large histone gene cluster on chromosome 6p22-p21.3.
Source: NCBI Gene 3012 — RefSeq curated summary.
At a glance
- GWAS associations: 16
- Clinical variants (ClinVar): 10 total
- Cancer dependency (DepMap): dependent in 29.3% of screened cell lines
- MANE Select transcript:
NM_021052
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:4724 |
| Approved symbol | H2AC8 |
| Name | H2A clustered histone 8 |
| Location | 6p22.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | H2A/a, H2A.1 |
| Ensembl gene | ENSG00000277075 |
| Ensembl biotype | protein_coding |
| OMIM | 602786 |
| Entrez | 3012 |
Gene structure
Transcript identifiers
Ensembl transcripts: 2 — 2 protein_coding
ENST00000303910, ENST00000850583
RefSeq mRNA: 1 — MANE Select: NM_021052
NM_021052
CCDS: CCDS4595
Canonical transcript exons
ENST00000303910 — 1 exons
| Exon | Start | End |
|---|---|---|
| ENSE00003978341 | 26216921 | 26217437 |
Expression profiles
Bgee: expression breadth ubiquitous, 181 present calls, max score 96.96.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 397.2778 / max 7341.0468, expressed in 1806 samples.
FANTOM5 promoters (2 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 66491 | 347.8680 | 1804 |
| 66492 | 49.4098 | 1711 |
Top tissues by expression
281 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| calcaneal tendon | UBERON:0003701 | 96.96 | gold quality |
| adrenal tissue | UBERON:0018303 | 96.29 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 92.19 | gold quality |
| monocyte | CL:0000576 | 90.10 | gold quality |
| mononuclear cell | CL:0000842 | 89.16 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 88.19 | gold quality |
| leukocyte | CL:0000738 | 87.97 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 87.20 | gold quality |
| tendon | UBERON:0000043 | 86.20 | gold quality |
| bone marrow cell | CL:0002092 | 85.70 | gold quality |
| right uterine tube | UBERON:0001302 | 84.28 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 82.35 | gold quality |
| prostate gland | UBERON:0002367 | 82.00 | gold quality |
| amniotic fluid | UBERON:0000173 | 80.62 | gold quality |
| colonic epithelium | UBERON:0000397 | 79.61 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 78.59 | gold quality |
| corpus epididymis | UBERON:0004359 | 78.07 | gold quality |
| blood | UBERON:0000178 | 76.45 | gold quality |
| skin of abdomen | UBERON:0001416 | 76.40 | gold quality |
| bone marrow | UBERON:0002371 | 75.59 | gold quality |
| granulocyte | CL:0000094 | 75.58 | gold quality |
| vagina | UBERON:0000996 | 74.90 | gold quality |
| spinal cord | UBERON:0002240 | 74.90 | gold quality |
| corpus callosum | UBERON:0002336 | 74.53 | gold quality |
| esophagus mucosa | UBERON:0002469 | 73.15 | gold quality |
| thymus | UBERON:0002370 | 72.86 | silver quality |
| apex of heart | UBERON:0002098 | 72.62 | gold quality |
| skin of leg | UBERON:0001511 | 72.57 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 72.23 | gold quality |
| ventricular zone | UBERON:0003053 | 72.01 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 9.98 |
Regulation
Is transcription factor: no
Upstream regulators (CollecTRI, top): E2F1, RBL1
miRNA regulators (miRDB)
17 targeting H2AC8, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-9-5P | 100.00 | 72.28 | 2361 |
| HSA-MIR-511-3P | 99.99 | 68.85 | 1467 |
| HSA-MIR-383-3P | 99.85 | 65.84 | 1359 |
| HSA-MIR-6756-5P | 99.82 | 67.97 | 2466 |
| HSA-MIR-6745 | 99.74 | 65.33 | 1321 |
| HSA-MIR-6766-5P | 99.68 | 67.70 | 2325 |
| HSA-MIR-29B-2-5P | 99.67 | 68.98 | 1726 |
| HSA-MIR-6512-3P | 99.65 | 66.07 | 1468 |
| HSA-MIR-6720-5P | 99.65 | 66.22 | 1459 |
| HSA-MIR-363-5P | 99.46 | 64.51 | 1015 |
| HSA-MIR-1276 | 99.36 | 68.18 | 1642 |
| HSA-MIR-146A-3P | 99.13 | 68.99 | 1881 |
| HSA-MIR-760 | 98.81 | 66.65 | 1392 |
| HSA-MIR-4483 | 98.09 | 64.12 | 1642 |
| HSA-MIR-8057 | 97.64 | 66.54 | 897 |
| HSA-MIR-6822-3P | 96.60 | 66.06 | 680 |
| HSA-MIR-1293 | 96.16 | 64.69 | 916 |
Functional genomics
DepMap (CRISPR cell-line fitness): dependent in 29.3% of screened cell lines.
Cross-species orthologs
22 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | H2ac7 | ENSMUSG00000071478 |
| rattus_norvegicus | Hist1h2ac | ENSRNOG00000090744 |
| drosophila_melanogaster | His2A:CG31618 | FBGN0051618 |
| drosophila_melanogaster | His2A:CG33808 | FBGN0053808 |
| drosophila_melanogaster | His2A:CG33814 | FBGN0053814 |
| drosophila_melanogaster | His2A:CG33817 | FBGN0053817 |
| drosophila_melanogaster | His2A:CG33820 | FBGN0053820 |
| drosophila_melanogaster | His2A:CG33823 | FBGN0053823 |
| drosophila_melanogaster | His2A:CG33826 | FBGN0053826 |
| drosophila_melanogaster | His2A:CG33829 | FBGN0053829 |
| drosophila_melanogaster | His2A:CG33832 | FBGN0053832 |
| drosophila_melanogaster | His2A:CG33835 | FBGN0053835 |
| drosophila_melanogaster | His2A:CG33838 | FBGN0053838 |
| drosophila_melanogaster | His2A:CG33841 | FBGN0053841 |
| drosophila_melanogaster | His2A:CG33844 | FBGN0053844 |
| drosophila_melanogaster | His2A:CG33847 | FBGN0053847 |
| drosophila_melanogaster | His2A:CG33850 | FBGN0053850 |
| drosophila_melanogaster | His2A:CG33853 | FBGN0053853 |
| drosophila_melanogaster | His2A:CG33856 | FBGN0053856 |
| drosophila_melanogaster | His2A:CG33859 | FBGN0053859 |
| drosophila_melanogaster | His2A:CG33862 | FBGN0053862 |
| drosophila_melanogaster | His2A:CG33865 | FBGN0053865 |
Paralogs (27): MACROH2A2 (ENSG00000099284), H2AZ2 (ENSG00000105968), MACROH2A1 (ENSG00000113648), H2AZ1 (ENSG00000164032), H2AC1 (ENSG00000164508), H2AC6 (ENSG00000180573), H2AC25 (ENSG00000181218), H2AC20 (ENSG00000184260), H2AC21 (ENSG00000184270), H2AX (ENSG00000188486), H2AC13 (ENSG00000196747), H2AC11 (ENSG00000196787), H2AC7 (ENSG00000196866), H2AL3 (ENSG00000229674), H2AJ (ENSG00000246705), H2AL1Q (ENSG00000249467), H2AB1 (ENSG00000274183), H2AC12 (ENSG00000274997), H2AC15 (ENSG00000275221), H2AC14 (ENSG00000276368), H2AC16 (ENSG00000276903), H2AB3 (ENSG00000277745), H2AB2 (ENSG00000277858), H2AC4 (ENSG00000278463), H2AC17 (ENSG00000278677), H2AC18 (ENSG00000288825), H2AC19 (ENSG00000288859)
Protein
Protein identifiers
Histone H2A type 1-B/E — P04908 (reviewed: P04908)
Alternative names: Histone H2A.2, Histone H2A/a, Histone H2A/m
All UniProt accessions (2): P04908, Q08AJ9
UniProt curated annotations — full annotation on UniProt →
Function. Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling.
Subunit / interactions. The nucleosome is a histone octamer containing two molecules each of H2A, H2B, H3 and H4 assembled in one H3-H4 heterotetramer and two H2A-H2B heterodimers. The octamer wraps approximately 147 bp of DNA.
Subcellular location. Nucleus. Chromosome.
Post-translational modifications. Deiminated on Arg-4 in granulocytes upon calcium entry. Monoubiquitination of Lys-120 (H2AK119Ub) by RING1, TRIM37 and RNF2/RING2 complex gives a specific tag for epigenetic transcriptional repression and participates in X chromosome inactivation of female mammals. It is involved in the initiation of both imprinted and random X inactivation. Ubiquitinated H2A is enriched in inactive X chromosome chromatin. Ubiquitination of H2A functions downstream of methylation of ‘Lys-27’ of histone H3 (H3K27me). H2AK119Ub by RNF2/RING2 can also be induced by ultraviolet and may be involved in DNA repair. Monoubiquitination of Lys-120 (H2AK119Ub) by TRIM37 may promote transformation of cells in a number of breast cancers. Following DNA double-strand breaks (DSBs), it is ubiquitinated through ‘Lys-63’ linkage of ubiquitin moieties by the E2 ligase UBE2N and the E3 ligases RNF8 and RNF168, leading to the recruitment of repair proteins to sites of DNA damage. Ubiquitination at Lys-14 and Lys-16 (H2AK13Ub and H2AK15Ub, respectively) in response to DNA damage is initiated by RNF168 that mediates monoubiquitination at these 2 sites, and ‘Lys-63’-linked ubiquitin are then conjugated to monoubiquitin; RNF8 is able to extend ‘Lys-63’-linked ubiquitin chains in vitro. Deubiquitinated by USP51 at Lys-14 and Lys-16 (H2AK13Ub and H2AK15Ub, respectively) after damaged DNA is repaired. H2AK119Ub and ionizing radiation-induced ‘Lys-63’-linked ubiquitination (H2AK13Ub and H2AK15Ub) are distinct events. Phosphorylation on Ser-2 (H2AS1ph) is enhanced during mitosis. Phosphorylation on Ser-2 by RPS6KA5/MSK1 directly represses transcription. Acetylation of H3 inhibits Ser-2 phosphorylation by RPS6KA5/MSK1. Phosphorylation at Thr-121 (H2AT120ph) by DCAF1 is present in the regulatory region of many tumor suppresor genes and down-regulates their transcription. Glutamine methylation at Gln-105 (H2AQ104me) by FBL is specifically dedicated to polymerase I. It is present at 35S ribosomal DNA locus and impairs binding of the FACT complex. Symmetric dimethylation on Arg-4 by the PRDM1/PRMT5 complex may play a crucial role in the germ-cell lineage. Crotonylation (Kcr) is specifically present in male germ cells and marks testis-specific genes in post-meiotic cells, including X-linked genes that escape sex chromosome inactivation in haploid cells. Crotonylation marks active promoters and enhancers and confers resistance to transcriptional repressors. It is also associated with post-meiotically activated genes on autosomes. Lactylated in macrophages by EP300/P300 by using lactoyl-CoA directly derived from endogenous or exogenous lactate, leading to stimulates gene transcription.
Similarity. Belongs to the histone H2A family.
RefSeq proteins (1): NP_066390* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR002119 | Histone_H2A | Family |
| IPR007125 | H2A/H2B/H3 | Domain |
| IPR009072 | Histone-fold | Homologous_superfamily |
| IPR032454 | Histone_H2A_C | Domain |
| IPR032458 | Histone_H2A_CS | Conserved_site |
Pfam: PF00125, PF16211
UniProt features (58 total): modified residue 36, helix 6, strand 4, cross-link 3, turn 3, initiator methionine 1, chain 1, region of interest 1, compositionally biased region 1, mutagenesis site 1, sequence conflict 1
Structure
Experimental structures (PDB)
356 structures, top 30 by resolution.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 7VZ4 | ELECTRON MICROSCOPY | 1.89 |
| 6ACL | X-RAY DIFFRACTION | 1.92 |
| 8I17 | X-RAY DIFFRACTION | 1.98 |
| 5B0Z | X-RAY DIFFRACTION | 1.99 |
| 5Y0D | X-RAY DIFFRACTION | 1.99 |
| 6IPU | X-RAY DIFFRACTION | 1.99 |
| 8UQA | X-RAY DIFFRACTION | 2.05 |
| 5Y0C | X-RAY DIFFRACTION | 2.09 |
| 8Q3E | X-RAY DIFFRACTION | 2.17 |
| 5X7X | X-RAY DIFFRACTION | 2.18 |
| 5AV6 | X-RAY DIFFRACTION | 2.2 |
| 5AV8 | X-RAY DIFFRACTION | 2.2 |
| 5AV9 | X-RAY DIFFRACTION | 2.2 |
| 5B31 | X-RAY DIFFRACTION | 2.2 |
| 6KE9 | X-RAY DIFFRACTION | 2.22 |
| 6IQ4 | X-RAY DIFFRACTION | 2.25 |
| 6JXD | X-RAY DIFFRACTION | 2.25 |
| 8KB5 | ELECTRON MICROSCOPY | 2.26 |
| 8UQ9 | X-RAY DIFFRACTION | 2.3 |
| 8Q3X | X-RAY DIFFRACTION | 2.3 |
| 8UQ8 | X-RAY DIFFRACTION | 2.34 |
| 5B32 | X-RAY DIFFRACTION | 2.35 |
| 8JLB | ELECTRON MICROSCOPY | 2.36 |
| 8YBJ | ELECTRON MICROSCOPY | 2.38 |
| 3AZG | X-RAY DIFFRACTION | 2.4 |
| 5AV5 | X-RAY DIFFRACTION | 2.4 |
| 5AVB | X-RAY DIFFRACTION | 2.4 |
| 5AVC | X-RAY DIFFRACTION | 2.4 |
| 6JR1 | X-RAY DIFFRACTION | 2.4 |
| 8JLD | ELECTRON MICROSCOPY | 2.48 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-P04908-F1 | 91.03 | 0.80 |
Antibody-complex structures (SAbDab): 8 — 6E0C, 6E0P, 7K5X, 7K5Y, 7K60, 7K61, 7K63, 8VFX
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (39): 10, 10, 10, 10, 10, 14, 14, 16, 37, 37, 37, 37, 75, 76, 96, 96, 96, 96, 96, 105 …
Mutagenesis-validated functional residues (1):
| Position | Phenotype |
|---|---|
| 2 | blocks the inhibition of transcription by rps6ka5/msk1. |
Function
Pathways and Gene Ontology
Reactome pathways
55 pathways
| ID | Pathway |
|---|---|
| R-HSA-110328 | Recognition and association of DNA glycosylase with site containing an affected pyrimidine |
| R-HSA-110329 | Cleavage of the damaged pyrimidine |
| R-HSA-110330 | Recognition and association of DNA glycosylase with site containing an affected purine |
| R-HSA-110331 | Cleavage of the damaged purine |
| R-HSA-1221632 | Meiotic synapsis |
| R-HSA-171306 | Packaging Of Telomere Ends |
| R-HSA-1912408 | Pre-NOTCH Transcription and Translation |
| R-HSA-201722 | Formation of the beta-catenin:TCF transactivating complex |
| R-HSA-212300 | PRC2 methylates histones and DNA |
| R-HSA-2299718 | Condensation of Prophase Chromosomes |
| R-HSA-2559580 | Oxidative Stress Induced Senescence |
| R-HSA-2559582 | Senescence-Associated Secretory Phenotype (SASP) |
| R-HSA-2559586 | DNA Damage/Telomere Stress Induced Senescence |
| R-HSA-3214815 | HDACs deacetylate histones |
| R-HSA-3214847 | HATs acetylate histones |
| R-HSA-3214858 | RMTs methylate histone arginines |
| R-HSA-427359 | SIRT1 negatively regulates rRNA expression |
| R-HSA-427389 | ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression |
| R-HSA-427413 | NoRC negatively regulates rRNA expression |
| R-HSA-5250924 | B-WICH complex positively regulates rRNA expression |
| R-HSA-5334118 | DNA methylation |
| R-HSA-5578749 | Transcriptional regulation by small RNAs |
| R-HSA-5617472 | Activation of anterior HOX genes in hindbrain development during early embryogenesis |
| R-HSA-5625886 | Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 |
| R-HSA-5689603 | UCH proteinases |
| R-HSA-5689880 | Ub-specific processing proteases |
| R-HSA-5689901 | Metalloprotease DUBs |
| R-HSA-606279 | Deposition of new CENPA-containing nucleosomes at the centromere |
| R-HSA-68616 | Assembly of the ORC complex at the origin of replication |
| R-HSA-73728 | RNA Polymerase I Promoter Opening |
MSigDB gene sets: 258 (showing top):
GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_UP, REACTOME_MEIOTIC_RECOMBINATION, REACTOME_DNA_REPLICATION, REACTOME_SIGNALING_BY_NOTCH, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_DN, REACTOME_MEIOTIC_SYNAPSIS, GOZGIT_ESR1_TARGETS_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, KONG_E2F3_TARGETS, REACTOME_ADHERENS_JUNCTIONS_INTERACTIONS, GOBP_NEGATIVE_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC, GOBP_PROTEIN_LOCALIZATION_TO_CHROMOSOME_CENTROMERIC_REGION, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM2, LE_EGR2_TARGETS_UP
GO Biological Process (4): chromatin organization (GO:0006325), negative regulation of cell population proliferation (GO:0008285), heterochromatin formation (GO:0031507), protein localization to CENP-A containing chromatin (GO:0061644)
GO Molecular Function (4): DNA binding (GO:0003677), structural constituent of chromatin (GO:0030527), protein heterodimerization activity (GO:0046982), protein binding (GO:0005515)
GO Cellular Component (5): nucleosome (GO:0000786), nucleus (GO:0005634), CENP-A containing nucleosome (GO:0043505), extracellular exosome (GO:0070062), chromosome (GO:0005694)
Reactome top-level categories
Rollup of top-12 pathways:
| Category | Pathways |
|---|---|
| Cellular Senescence | 3 |
| Chromatin modifying enzymes | 3 |
| Depyrimidination | 2 |
| Depurination | 2 |
| Negative epigenetic regulation of rRNA expression | 2 |
| Positive epigenetic regulation of rRNA expression | 2 |
| Meiosis | 1 |
| Telomere Maintenance | 1 |
| Pre-NOTCH Expression and Processing | 1 |
| TCF dependent signaling in response to WNT | 1 |
| Epigenetic regulation of gene expression | 1 |
| Mitotic Prophase | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| chromatin | 2 |
| cellular component organization | 1 |
| cell population proliferation | 1 |
| regulation of cell population proliferation | 1 |
| negative regulation of cellular process | 1 |
| cellular component assembly | 1 |
| heterochromatin boundary formation | 1 |
| negative regulation of gene expression, epigenetic | 1 |
| heterochromatin organization | 1 |
| protein localization to chromatin | 1 |
| protein localization to chromosome, centromeric region | 1 |
| nucleic acid binding | 1 |
| structural molecule activity | 1 |
| protein dimerization activity | 1 |
| binding | 1 |
| protein-DNA complex | 1 |
| intracellular membrane-bounded organelle | 1 |
| nucleosome | 1 |
| CENP-A containing chromatin | 1 |
| extracellular vesicle | 1 |
| intracellular membraneless organelle | 1 |
Protein interactions and networks
STRING
2092 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| H2AC8 | H2BC21 | Q16778 | 940 |
| H2AC8 | H4C16 | P02304 | 856 |
| H2AC8 | H3C1 | P02295 | 846 |
| H2AC8 | H1-1 | Q02539 | 743 |
| H2AC8 | H2BC8 | P02278 | 690 |
| H2AC8 | H2BC5 | P58876 | 689 |
| H2AC8 | H2BC3 | P33778 | 634 |
| H2AC8 | H2BC12 | O60814 | 606 |
| H2AC8 | H1-5 | P16401 | 599 |
| H2AC8 | H2BC14 | Q99879 | 591 |
| H2AC8 | H3C14 | Q71DI3 | 563 |
| H2AC8 | H3-3A | P06351 | 561 |
| H2AC8 | UBA1 | P22314 | 462 |
| H2AC8 | H2BC17 | P23527 | 452 |
| H2AC8 | H1-2 | P16403 | 438 |
IntAct
215 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| H2AC4 | H4C16 | psi-mi:“MI:0915”(physical association) | 0.900 |
| H2AC4 | H2BC11 | psi-mi:“MI:0915”(physical association) | 0.850 |
| H2AC4 | H2BC11 | psi-mi:“MI:0407”(direct interaction) | 0.850 |
| CXXC1 | SETD1A | psi-mi:“MI:0914”(association) | 0.760 |
| XPC | CETN3 | psi-mi:“MI:0914”(association) | 0.730 |
| H2AC4 | PPM1G | psi-mi:“MI:0914”(association) | 0.670 |
| H3-4 | H2AC4 | psi-mi:“MI:0915”(physical association) | 0.590 |
| HP1BP3 | H2AC4 | psi-mi:“MI:0915”(physical association) | 0.560 |
| H2AC4 | H2BC15 | psi-mi:“MI:0915”(physical association) | 0.560 |
| H2AC4 | H3C13 | psi-mi:“MI:0915”(physical association) | 0.550 |
| H2AC4 | H2BC12 | psi-mi:“MI:0915”(physical association) | 0.530 |
| CBX6 | IGF2BP3 | psi-mi:“MI:0914”(association) | 0.530 |
| CBX1 | KPNA3 | psi-mi:“MI:0914”(association) | 0.530 |
| H1-6 | ZNF724 | psi-mi:“MI:0914”(association) | 0.530 |
| HP1BP3 | IPO8 | psi-mi:“MI:0914”(association) | 0.530 |
| UBE3A | HERC2 | psi-mi:“MI:0914”(association) | 0.500 |
| psi-mi:“MI:0915”(physical association) | 0.500 |
BioGRID (1018): HIST1H2AE (Affinity Capture-MS), HIST1H2AB (Biochemical Activity), HIST1H2AB (Reconstituted Complex), HIST1H2AB (Affinity Capture-Western), HIST1H2AB (Affinity Capture-Western), UBC (Affinity Capture-Western), HIST1H2AE (Affinity Capture-RNA), HIST1H2AE (Affinity Capture-RNA), HIST1H2AE (Affinity Capture-RNA), HIST1H2AB (Biochemical Activity), HIST1H2AB (Biochemical Activity), HIST1H2AB (Biochemical Activity), HIST1H2AB (Biochemical Activity), HIST1H2AB (Reconstituted Complex), HIST1H2AB (Affinity Capture-Western)
ESM2 similar proteins: A1A4R1, A9UMV8, C0HKE1, C0HKE2, C0HKE3, C0HKE4, C0HKE5, C0HKE6, C0HKE7, C0HKE8, C0HKE9, P02262, P02263, P02270, P04908, P06897, P0C0S8, P0C0S9, P0C169, P0C170, P0CC09, P13912, P19178, P20671, P21896, P27325, P35061, P35062, P70082, P84052, Q07135, Q16777, Q3ZBX9, Q4FZT6, Q4R3X5, Q64522, Q64523, Q64598, Q6FI13, Q6GSS7
Diamond homologs: A0A097I1R9, A0A097I2B5, A0A0D2UG83, A1A4R1, A1CJ10, A1D8G8, A3LXE7, A3LZZ0, A5DBG4, A5DJJ2, A5DWF1, A5DXC6, A9UMV8, C0HKE1, C0HKE2, C0HKE3, C0HKE4, C0HKE5, C0HKE6, C0HKE7, C0HKE8, C0HKE9, L7HZV6, O74268, P02262, P02263, P02264, P04908, P04909, P04910, P04911, P04912, P06897, P07793, P08844, P0C0S8, P0C0S9, P0C169, P0C170, P0C952
SIGNOR signaling
8 interactions.
| A | Effect | B | Mechanism |
|---|---|---|---|
| KDM4C | “down-regulates activity” | H2AC4 | demethylation |
| H2AC4 | “form complex” | “Nucleosome_H3.3 variant” | binding |
| SLBP | “up-regulates quantity by expression” | H2AC4 | “translation regulation” |
| DZIP3 | “up-regulates activity” | H2AC4 | monoubiquitination |
| H2AC4 | “form complex” | “CENP-A nucleosome” | binding |
| H2AC4 | “form complex” | “Nucleosome_H3.1 variant” | binding |
| H2AC4 | “form complex” | “Nucleosome_H3.1t variant” | binding |
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 186 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 6 | 31.7× | 3e-07 |
| Replacement of protamines by nucleosomes in the male pronucleus | 11 | 23.6× | 2e-11 |
| Packaging Of Telomere Ends | 12 | 20.8× | 1e-11 |
| Recognition and association of DNA glycosylase with site containing an affected purine | 12 | 19.3× | 2e-11 |
| Cleavage of the damaged purine | 12 | 19.3× | 2e-11 |
| RNA Polymerase I Promoter Opening | 13 | 18.9× | 7e-12 |
| ChAHP complex assembly | 13 | 18.9× | 7e-12 |
| Inhibition of DNA recombination at telomere | 14 | 18.5× | 2e-12 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| negative regulation of DNA recombination | 5 | 34.9× | 1e-04 |
| chromosome condensation | 5 | 26.2× | 3e-04 |
| nucleosome assembly | 18 | 15.7× | 8e-14 |
| chromatin organization | 11 | 6.8× | 2e-04 |
| chromatin remodeling | 12 | 5.4× | 5e-04 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
10 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 10 |
| Likely benign | 0 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
54 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 6:26217088:C:T | donor_gain | 0.8000 |
| 6:26217018:C:G | donor_gain | 0.7400 |
| 6:26217199:G:GT | donor_gain | 0.6200 |
| 6:26217254:C:G | donor_gain | 0.6100 |
| 6:26217230:C:G | donor_gain | 0.6000 |
| 6:26217251:GAGC:G | donor_gain | 0.6000 |
| 6:26217091:C:G | donor_gain | 0.5400 |
| 6:26217195:A:AG | donor_gain | 0.5200 |
| 6:26217258:A:G | donor_gain | 0.5200 |
| 6:26217271:T:TA | donor_gain | 0.5200 |
| 6:26217087:GCAAC:G | donor_gain | 0.4900 |
| 6:26217122:GT:G | donor_gain | 0.4900 |
| 6:26217258:A:AG | donor_gain | 0.4800 |
| 6:26217012:C:T | donor_gain | 0.4600 |
| 6:26217262:GCTTC:G | donor_gain | 0.4500 |
| 6:26217339:A:T | donor_gain | 0.4500 |
| 6:26217250:G:GT | donor_gain | 0.4200 |
| 6:26217361:C:T | donor_gain | 0.4200 |
| 6:26217291:G:T | donor_gain | 0.3800 |
| 6:26217170:C:G | donor_gain | 0.3700 |
| 6:26216982:G:GT | donor_gain | 0.3500 |
| 6:26217273:GC:G | donor_gain | 0.3500 |
| 6:26217358:GG:G | donor_gain | 0.3300 |
| 6:26217359:GG:G | donor_gain | 0.3300 |
| 6:26217290:G:GT | donor_gain | 0.3200 |
| 6:26217314:G:GT | donor_gain | 0.3200 |
| 6:26216989:A:T | donor_gain | 0.3100 |
| 6:26217272:CG:C | donor_gain | 0.3100 |
| 6:26217313:GGCC:G | donor_gain | 0.3100 |
| 6:26217128:C:G | donor_gain | 0.3000 |
AlphaMissense
818 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 6:26217146:T:C | Y58H | 1.000 |
| 6:26217171:T:C | L66P | 1.000 |
| 6:26217176:G:C | G68R | 1.000 |
| 6:26217177:G:A | G68D | 1.000 |
| 6:26217186:C:A | A71D | 1.000 |
| 6:26217231:T:C | L86P | 1.000 |
| 6:26217245:G:C | D91H | 1.000 |
| 6:26217246:A:C | D91A | 1.000 |
| 6:26217246:A:T | D91V | 1.000 |
| 6:26217045:T:A | L24H | 0.999 |
| 6:26217045:T:C | L24P | 0.999 |
| 6:26217051:T:C | F26S | 0.999 |
| 6:26217057:T:A | V28D | 0.999 |
| 6:26217059:G:C | G29R | 0.999 |
| 6:26217060:G:A | G29D | 0.999 |
| 6:26217107:G:T | G45W | 0.999 |
| 6:26217108:G:A | G45E | 0.999 |
| 6:26217134:G:C | A54P | 0.999 |
| 6:26217135:C:A | A54E | 0.999 |
| 6:26217143:G:A | E57K | 0.999 |
| 6:26217144:A:T | E57V | 0.999 |
| 6:26217150:T:C | L59P | 0.999 |
| 6:26217155:G:C | A61P | 0.999 |
| 6:26217156:C:A | A61D | 0.999 |
| 6:26217158:G:A | E62K | 0.999 |
| 6:26217159:A:T | E62V | 0.999 |
| 6:26217167:G:A | E65K | 0.999 |
| 6:26217173:G:C | A67P | 0.999 |
| 6:26217174:C:A | A67D | 0.999 |
| 6:26217176:G:T | G68C | 0.999 |
dbSNP variants (sampled 300 via entrez): RS1001787573 (6:26215383 A>T), RS1002538521 (6:26216563 G>A,C), RS1002793227 (6:26217725 T>C), RS1002799030 (6:26216322 C>A,T), RS1006759405 (6:26217577 C>A,T), RS1007376861 (6:26214994 G>A,T), RS1010491655 (6:26215878 A>C,G,T), RS1011933595 (6:26215037 G>A,T), RS1012510149 (6:26217554 T>G), RS1012883659 (6:26217386 C>A,G,T), RS1013609205 (6:26217766 A>G), RS1014291705 (6:26215349 T>C), RS1014365317 (6:26215645 C>G), RS1014862039 (6:26217598 TA>T), RS1014881034 (6:26216139 T>C)
Disease associations
OMIM: gene MIM:602786 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
16 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST004521_113 | Autism spectrum disorder or schizophrenia | 3.000000e-19 |
| GCST004521_142 | Autism spectrum disorder or schizophrenia | 2.000000e-09 |
| GCST004521_169 | Autism spectrum disorder or schizophrenia | 4.000000e-14 |
| GCST004521_69 | Autism spectrum disorder or schizophrenia | 8.000000e-24 |
| GCST004521_83 | Autism spectrum disorder or schizophrenia | 1.000000e-13 |
| GCST007294_143 | Body fat distribution (trunk fat ratio) | 5.000000e-29 |
| GCST007294_82 | Body fat distribution (trunk fat ratio) | 1.000000e-48 |
| GCST007295_120 | Body fat distribution (leg fat ratio) | 2.000000e-46 |
| GCST007295_91 | Body fat distribution (leg fat ratio) | 1.000000e-26 |
| GCST010141_1 | Beef consumption | 7.000000e-13 |
| GCST010143_19 | Meat-related diet | 5.000000e-13 |
| GCST010143_31 | Meat-related diet | 7.000000e-09 |
| GCST010143_5 | Meat-related diet | 4.000000e-09 |
| GCST012226_43 | Waist circumference adjusted for body mass index | 4.000000e-13 |
| GCST012227_893 | Hip circumference adjusted for BMI | 2.000000e-22 |
| GCST90020028_935 | Hip circumference adjusted for BMI | 3.000000e-37 |
EFO canonical traits (4, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004341 | body fat distribution |
| EFO:0008111 | diet measurement |
| EFO:0007789 | BMI-adjusted waist circumference |
| EFO:0008039 | BMI-adjusted hip circumference |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
51 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| (+)-JQ1 compound | increases expression, decreases expression | 5 |
| Benzo(a)pyrene | increases expression | 3 |
| Estradiol | affects expression, increases expression | 3 |
| sodium arsenite | decreases expression | 2 |
| Quercetin | decreases expression, increases expression | 2 |
| Silicon Dioxide | increases expression | 2 |
| Tetrachlorodibenzodioxin | increases expression | 2 |
| Cyclosporine | decreases expression, increases expression | 2 |
| Cadmium Chloride | increases abundance, increases expression | 2 |
| urushiol | decreases expression | 1 |
| bisphenol A | decreases expression | 1 |
| methylselenic acid | decreases expression | 1 |
| 2-methyl-4-isothiazolin-3-one | decreases expression | 1 |
| thallium sulfate | decreases expression | 1 |
| tris(1,3-dichloro-2-propyl)phosphate | decreases expression | 1 |
| cobaltous chloride | decreases expression | 1 |
| ferrous chloride | increases expression | 1 |
| 2,3-bis(3’-hydroxybenzyl)butyrolactone | affects cotreatment, decreases expression | 1 |
| deguelin | increases expression | 1 |
| 2-palmitoylglycerol | increases expression | 1 |
| fenpyroximate | increases expression | 1 |
| 4-chloro-N-((4-(1,1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide | increases expression | 1 |
| dimethylarsinous acid | increases expression | 1 |
| pyrimidifen | increases expression | 1 |
| licochalcone B | increases expression | 1 |
| incobotulinumtoxinA | decreases expression | 1 |
| Acetaminophen | increases expression | 1 |
| Air Pollutants | increases abundance, increases expression | 1 |
| Berberine | decreases expression | 1 |
| Cadmium | increases abundance, increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.